![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » NOSTRUM PHARMACEUTICALS OBTAINS WORLDWIDE LICENSING RIGHTS FROM IMTECH FOR CLINICAL DEVELOPMENT OF A NOVEL CLOT BUSTING THERAPEUTIC PROTEIN
NOSTRUM PHARMACEUTICALS OBTAINS WORLDWIDE LICENSING RIGHTS FROM IMTECH FOR CLINICAL DEVELOPMENT OF A NOVEL CLOT BUSTING THERAPEUTIC PROTEIN
July 28, 2006
Pharmaceuticals Inc., a privately held company based in Kendall Park, New Jersey, announced that it has obtained a worldwide license from Institute of Microbial Technology (IMTECH), Chandigarh, India, to carry out clinical development and commercialization of a novel clot busting therapeutic protein.
BioSpace
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct